BridgeMD
Compares treatment options for Coronary Artery Disease
Official title Surgical Versus Percutaneous Revascularization in Patients With Reduced Left Ventricular Function (STICH 3.0-NL)
ClinicalTrials.gov ID: NCT07269366
What this study is testing
- What it's testing
- This randomized multicenter trial compares coronary artery bypass grafting (CABG) with percutaneous coronary intervention (PCI) in 358 patients with ischemic left ventricular dysfunction and multivessel coronary disease. The study evaluates differences in survival, major cardiovascular events, and quality of life over 4 years, and contributes to the international STICH 3.0 collaboration assessing long-term outcomes.
- Time commitment: about 4 years
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years
- LVEF≤ 40%
- Angina pectoris, CCS≥2 and/or hospitalization for ACS or heart failure within 1 year prior to randomization
- Multivessel CAD (2-3 vessel-disease with coronary lesions \>70% and involvement of proximal LAD, and/or LM stenosis of \>50%). Target vessels are...
- Clinical and angiographical characteristics suitable for isolated coronary revascularization both by CABG or PCI according to the judgment of the...
You likely can't join if
- ACS \< 48 hours before randomization
- Valvular/structural heart disease requiring intervention
- Contra-indications to DAPT
- Non-cardiac condition with life expectancy \< 1 year
- Previous CABG
- Decompensated HF at the time of inclusion
See the full eligibility criteria
- Age ≥ 18 years
- LVEF≤ 40%
- Angina pectoris, CCS≥2 and/or hospitalization for ACS or heart failure within 1 year prior to randomization
- Multivessel CAD (2-3 vessel-disease with coronary lesions \>70% and involvement of proximal LAD, and/or LM stenosis of \>50%). Target vessels are determined by the local Heart Time
- Clinical and angiographical characteristics suitable for isolated coronary revascularization both by CABG or PCI according to the judgment of the local Heart Team
- Written informed consent
- ACS \< 48 hours before randomization
- Valvular/structural heart disease requiring intervention
- Contra-indications to DAPT
- Non-cardiac condition with life expectancy \< 1 year
- Previous CABG
- Decompensated HF at the time of inclusion
The study team makes the final eligibility decision.
Where it's taking place
- Groningen, Netherlands
Compensation & support
A stipend or compensation may be offered.
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 4 years per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Groningen, Netherlands. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.